Clinical Trial Search

Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months

Primary: Response Rate — 0 percentage of patients responding

Primary: Observed Response Rate. — 0 Percentage of Participants

Primary: Overall Survival (OS) — 11.96 Months

Primary: Objective Tumor Response (Defined as Partial [PR] or Complete Response [CR] by RECIST Criteria) — 0 participants

Primary: Overall Survival — 3.6; 3.5 years

Primary: Number of Patients With Each Response in "Good Risk" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression]) — 0…

Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months

Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants

Primary: Maximum Tolerated Dose (MTD) of Everolimus — 2.5 mg

Primary: Overall Response Rate (ORR) — 39.1 percentage of participants

Primary: Time to Progression — 6.6 months

Primary: Maximum Tolerated Dose (MTD) of Docetaxel When Given in Combination With Oxaliplatin and Fluorouracil (Phase I) — 50 mg/m2

Primary: CRLX101 (CPT) Uptake in Tumor and Nearby Normal Tissue — 9; 0; 0; 9 Participants — p=<0.01

Primary: Progression-free Survival (PFS) — 5.72; 5.39 months

Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants

Primary: Progression-Free Survival (PFS) — 6.4; 6.7 months — p=0.886

Primary: True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST) — 3; 1 participants

Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants

Primary: Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus…

Primary: Number of Participants With an Objective Response — 25; 22 Participants

Primary: Median Progression-free Survival (PFS) — 8.77; 8.35 months — p=0.874

Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants

Primary: Overall Survival (OS) — 5.2; 3.8 months — p=0.0473

Primary: Proportion of Participants With Improved Sensitivity for Detection of Early-stage Gastric Cancer in CDH1 Germline Mutation Carriers Compared to the Cambridge Method — 1…

Primary: Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1)…

Primary: Overall Response Rate — 1; 0; 4; 1 participants

Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants

Primary: Overall Survival (OS) in Participants Treated With Nivolumab Plus Chemotherapy vs Chemotherapy With PD-L1 CPS ≥ 5 — 14.39; 11.10 Months — p=<0.0001

Primary: Median Overall Survival — 4.3; 13.8; 14.6; 15.2 Months